Skip to main content

Table 2 EGFR enzyme activity of compounds 11d, 12c and 12d

From: Synthesis of phthalazine-based derivatives as selective anti-breast cancer agents through EGFR-mediated apoptosis: in vitro and in silico studies

Compound

EGFR

% of inhibition at [10 µM]

IC50 [nM] ± SD*

11d

92.9 ± 2.08

79.6 ± 1.35

12c

96.2 ± 2.04

65.4 ± 1.12

12d

97.6 ± 2.49

21.4 ± 0.67

Erlotinib

93.9 ± 2.68

80.1 ± 1.21

  1. *Values are expressed as an average of three independent replicates. “IC50 values were calculated using sigmoidal non-linear regression curve fit of percentage inhibition against five concentrations of each compound”